View Cart  

Panel Gives Nod to Novo’s Long-Acting Insulin Despite Heart Concerns

A A
FDA advisers voted 8–4 Thursday in support of approval for Novo Nordisk’s ultra-long acting insulin candidates Tresiba and Ryzodeg for Type 1 and Type 2 diabetes despite lingering worries about cardiovascular effects.

To View This Article:

Login

Buy This Article Now

Add this article to your cart for $25.00